Hospital Arnau de Vilanova-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study

    Minerva Anestesiologica, Vol. 88, Núm. 4, pp. 259-271

2018

  1. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

2017

  1. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

2015

  1. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

  2. Febrile young infants with altered urinalysis at low risk for invasive bacterial infection. A Spanish pediatric emergency research network's study

    Pediatric Infectious Disease Journal, Vol. 34, Núm. 1, pp. 17-21

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248

2011

  1. Community-acquired respiratory coinfection in critically III patients with pandemic 2009 influenza A(H1N1) virus

    Chest, Vol. 139, Núm. 3, pp. 555-562

  2. Impact of obesity in patients infected with 2009 influenza A(H1N1)

    Chest, Vol. 139, Núm. 2, pp. 382-386

  3. Severe pandemic (H1N1)v influenza A infection: Report on the first deaths in Spain

    Respirology, Vol. 16, Núm. 1, pp. 78-85

2005

  1. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 55, Núm. 2, pp. 197-202